Antibody responses of SARS-CoV-2 vaccines amongst health care workers in a tertiary care hospital in Tripura, India: A cross-sectional study

Background: Vaccines against COVID-19 plays an important role in limiting the spread of SARS-CoV-2 infections and also in curbing mortality and morbidity due to COVID-19. Objective: To estimate the anti-spike antibody response after receiving the second dose of SARS-CoV-2 vaccines amongst health car...

Full description

Saved in:
Bibliographic Details
Main Authors: Chanda Mog (Author), Sibabrata Bhattacharya (Author), Subrata Baidya (Author), Shampa Das (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2022-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Vaccines against COVID-19 plays an important role in limiting the spread of SARS-CoV-2 infections and also in curbing mortality and morbidity due to COVID-19. Objective: To estimate the anti-spike antibody response after receiving the second dose of SARS-CoV-2 vaccines amongst health care workers of a tertiary care hospital in Tripura, India. Materials and Method: A cross- sectional study was conducted from 1 July to 20 August 2021 at Agartala Government Medical College and GBP Hospital, Agartala among 561 health care workers who had received first and second doses of SARS-CoV-2 vaccines and had completed 14 days after receiving the second dose. Results: The present study showed that health care workers who had received both doses of COVID-19 vaccine had 99.5% seropositivity to anti-spike antibody. The median SARS-CoV-2 anti-spike antibody titter was 250 with an IQR (211.55-250). Seropositivity rate was higher among Covishield recipients (99.8% [550/551]) as compared to Covaxin recipients (80% [8/10]) and it was found to be statistically significant (P = 0.000). Conclusion: The present study suggests that a good immune response was elicited against spike antigen of SARS-CoV-2 after two complete doses of Covishield (ChAdOx1-nCoV-19) or Covaxin (BBV152).
Item Description:0970-0218
1998-3581
10.4103/ijcm.ijcm_71_22